RC88

DRUG4 trials

Sponsors

RemeGen Co., Ltd.

Conditions

Advanced Solid TumoursEpithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerSolid Tumor

Phase 1

A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

CompletedNCT04175847

RemeGen Co., Ltd.Solid Tumor

Start: 2020-04-14End: 2025-12-31Updated: 2026-01-07

A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours

CompletedNCT05508334

RemeGen Co., Ltd.Advanced Solid Tumours

Start: 2023-01-30End: 2025-11-26Updated: 2025-12-22

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

RecruitingNCT05804526

RemeGen Co., Ltd.Advanced Solid Tumours

Start: 2023-07-19End: 2025-12-31Target: 82Updated: 2024-04-30

Phase 2

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

CompletedNCT06173037

RemeGen Co., Ltd.Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Start: 2024-01-19End: 2025-12-31Updated: 2026-01-07

Related Papers

Abstract 2862: Anti MSLN ADC RC88 engages unique binding to target positive tumor cells with less interference from the soluble MSLN protein

Cancer Research2025-04-21

The efficacy and safety of RC88 in patients with ovarian cancer, non-squamous-non-small-cell lung-carcinoma and cervical cancer: Results from a first-in-human phase 1/2 study.

Journal of Clinical Oncology2024-06-019 citations